238 related articles for article (PubMed ID: 36142862)
1. The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function.
Bengtson C; Silswal N; Baumlin N; Yoshida M; Dennis J; Yerrathota S; Kim M; Salathe M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142862
[TBL] [Abstract][Full Text] [Related]
2. Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies.
Kim MD; Bengtson CD; Yoshida M; Niloy AJ; Dennis JS; Baumlin N; Salathe M
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35446787
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.
Lutful Kabir F; Ambalavanan N; Liu G; Li P; Solomon GM; Lal CV; Mazur M; Halloran B; Szul T; Gerthoffer WT; Rowe SM; Harris WT
Am J Respir Crit Care Med; 2018 Mar; 197(5):632-643. PubMed ID: 29232160
[TBL] [Abstract][Full Text] [Related]
4. TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis.
Hejenkowska ED; Mitash N; Donovan JE; Chandra A; Bertrand C; De Santi C; Greene CM; Mu F; Swiatecka-Urban A
J Innate Immun; 2023; 15(1):629-646. PubMed ID: 37579743
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
6. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
7. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A
Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
9. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
[TBL] [Abstract][Full Text] [Related]
10. Transforming Growth Factor-β1 Selectively Recruits microRNAs to the RNA-Induced Silencing Complex and Degrades CFTR mRNA under Permissive Conditions in Human Bronchial Epithelial Cells.
Mitash N; Mu F; Donovan JE; Myerburg MM; Ranganathan S; Greene CM; Swiatecka-Urban A
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590401
[TBL] [Abstract][Full Text] [Related]
11. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232697
[TBL] [Abstract][Full Text] [Related]
12. CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare
Lefferts JW; Bierlaagh MC; Kroes S; Nieuwenhuijze NDA; Sonneveld van Kooten HN; Niemöller PJ; Verburg TF; Janssens HM; Muilwijk D; van Beuningen SFB; van der Ent CK; Beekman JM
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833986
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
14. Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.
Saint-Criq V; Wang Y; Delpiano L; Lin J; Sheppard DN; Gray MA
J Cyst Fibros; 2021 Sep; 20(5):843-850. PubMed ID: 34020896
[TBL] [Abstract][Full Text] [Related]
15. Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.
Livnat G; Dagan A; Heching M; Shmueli E; Prais D; Yaacoby-Bianu K; Stein N; Mei-Zahav M; Gur M; Cohen-Cymberknoh M; Shteinberg M
J Cyst Fibros; 2023 May; 22(3):450-455. PubMed ID: 36372699
[TBL] [Abstract][Full Text] [Related]
16. CFTR Modulators: Current Status and Evolving Knowledge.
Regard L; Martin C; Da Silva J; Burgel PR
Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
[TBL] [Abstract][Full Text] [Related]
17. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
18. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.
Borgo C; D'Amore C; Capurro V; Tomati V; Sondo E; Cresta F; Castellani C; Pedemonte N; Salvi M
Cell Mol Life Sci; 2022 Mar; 79(4):192. PubMed ID: 35292885
[TBL] [Abstract][Full Text] [Related]
19. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
20. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E; Burgel PR; Hatton A; Bouazza N; Chevalier B; Macey J; Leroy S; Durieu I; Weiss L; Grenet D; Stremler N; Ohlmann C; Reix P; Porzio M; Roux Claude P; Rémus N; Douvry B; Montcouquiol S; Cosson L; Mankikian J; Languepin J; Houdouin V; Le Clainche L; Guillaumot A; Pouradier D; Tissot A; Priou P; Mély L; Chedevergne F; Lebourgeois M; Lebihan J; Martin C; Zavala F; Da Silva J; Lemonnier L; Kelly-Aubert M; Golec A; Foucaud P; Marguet C; Edelman A; Hinzpeter A; de Carli P; Girodon E; Sermet-Gaudelus I; Pranke I;
Eur Respir J; 2023 Oct; 62(4):. PubMed ID: 37696564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
